newsfilter
← Latest News
GlobeNewswire·

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations